EGFR-mutant lung adenocarcinoma transforming to small cell lung cancer during targeted therapy

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion, TP53 mutation, TMB 11 mut/Mb

Metastatic Site: cervical lymph nodes

At the last follow-up in February 2024, 32 months after diagnosis, she was alive and both the primary lung lesion and cervical lymph-node metastasis had decreased on combined chemotherapy, immunotherapy and targeted therapy.

PubMed CentralRead more →

Seven-year response journey in EGFR-mutated metastatic lung adenocarcinoma

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: pleura, brain

About 7 years after presentation with metastatic lung adenocarcinoma, he remained on targeted therapy. Gefitinib controlled the disease for 5 years; after brain progression, osimertinib followed by stereotactic radiation produced a complete intracranial response.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Leah's Patient Story

Patient Info: Leah Phillips, Female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: bone (spine, pelvis); malignant right pleural…

As of July 2024, Leah remained on daily Tagrisso with stable Stage IV EGFR-mutated lung cancer, no reported progression, healing/sclerotic bone metastases, and durable response for more than 4 years.

The Patient StoryRead more →

Near-complete response to osimertinib in Stage IV lung adenocarcinoma with rare EGFR mutations

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR S768I mutation, PD-L1 TPS 2%

Metastatic Site: pleura, bone, lymph nodes

After progression on vinorelbine and carboplatin, osimertinib produced a metabolic complete response by December 2023 and a near-complete radiologic response in March 2024. He remained on osimertinib with good tolerance and stable clinical condition.

PubMed CentralRead more →

EGFR-mutated lung cancer treated with osimertinib during tuberculosis therapy

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: pleura, left axillary lymph node

Osimertinib maintained a partial response throughout 9 months of tuberculosis treatment, with no new abdominal or brain lesions. By the end of tuberculosis treatment, she was more than 7 years from her original lung-cancer diagnosis.

PubMed CentralRead more →

EGFR-mutated lung cancer with later small-cell transformation

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: EGFR L858R mutation; acquired EGFR T790M mutation

Metastatic Site: pleura/chest wall, ribs, brain, meninges,…

Disease progressed through multiple lines of therapy with brain and meningeal involvement. He died in September 2021, more than 9 years after his original 2012 diagnosis.

PubMed CentralRead more →

More than five years with EGFR-mutated lung cancer and untreated brain metastases

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: EGFR L858R mutation; acquired EGFR T790M mutation

Metastatic Site: brain, pleura

Zorifertinib produced partial responses in both brain and extracranial disease, with 3 years of progression-free survival and more than 4 years of intracranial control. By December 2023, she remained alive on aumolertinib with overall survival of more than 65 months, or 5+ years, from treatment start.

PubMed CentralRead more →

Jeff

Patient Info: Jeff, Male | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: brain|bones|lymph nodes

The lung mass shrank, 5 brain lesions and the involved lymph node had no evidence of disease, and Jeff described his condition as stable while continuing osimertinib and bone-strengthening infusions.

Lung Cancer Research FoundationRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Anne's Patient Story

Patient Info: Anne Laporte, Female | Stage IV

Biomarkers: EGFR-mutated; several additional mutations mentioned but not specified

Metastatic Site: Spine; liver; lymph nodes

As of March 2024, Anne was living with Stage IVB EGFR-mutated NSCLC on a clinical trial after progression on Tagrisso, with early signs of decreased tumor burden and major improvement in pain.

The Patient StoryRead more →

EGFR L858R/S768I lung adenocarcinoma with more than 5 years of survival after targeted therapy

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: EGFR L858R and S768I compound mutation

Metastatic Site: bone, brain

He died on August 15, 2022, about 5 years and 4 months after his April 2017 presentation; afatinib had provided more than 3 years of disease control before later bone and brain progression.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Ashley's Patient Story

Patient Info: Ashley, Female | Stage IV

Biomarkers: EGFR T790M mutation

Metastatic Site: Both lungs / bilateral lung nodules

As of March 2024, Ashley was living with Stage IV EGFR-mutated NSCLC controlled on daily Tagrisso for 43 months, with stable scans but no cancer-free or NED claim.

The Patient StoryRead more →

EGFR-mutated stage IV lung cancer complicated by radiation lung injury and severe COVID-19

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: EGFR mutation; TP53 mutation

Metastatic Site: bone

Osimertinib produced a significant reduction in the lung lesions. She remained alive at the last follow-up in July 2023 after recovering from severe COVID-19 and treatment-related lung complications.

PubMed CentralRead more →

Stage IV EGFR Lung Cancer: Ivy's Survivor Story

Patient Info: Ivy E., Female, 40s | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Bone: elbow, cervical spine/neck, rib, pelvis; brain

As of January 2024, Ivy reported no evidence of disease 1 year after right upper lobectomy, after years of response to EGFR-targeted therapy for initially Stage IV lung cancer.

The Patient StoryRead more →

Stage IV enteric-type lung adenocarcinoma with EGFR mutations and MSI-high disease

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M; MSI-high; high tumor mutation burden; MLH1 mutation; pMMR; PD-L1-negative

Metastatic Site: lung, pleura

The cancer progressed through multiple targeted, chemotherapy, and immunotherapy regimens. He died about 30 months after the initial diagnosis.

PubMed CentralRead more →

Stage IV EGFR-Mutant Lung Adenocarcinoma Responding to Osimertinib

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: EGFR L833V/H835L mutations; PD-L1 50%; CDK4 amplification; MDM2 amplification

Metastatic Site: contralateral lung, brain

After 3 months of osimertinib, the right upper lobe lesion had decreased and right hilar lymphadenopathy had resolved. The brain lesion remained stable, and subsequent imaging continued to show improvement in the lung lesion.

PubMed CentralRead more →

Lung cancer recurrence in the thyroid, initially mistaken for thyroid cancer

Patient Info: Anonymized, Male | Stage IV

Biomarkers: EGFR exon 19 deletion; TTF-1-positive; Napsin A-positive; PAX8-negative; thyroglobulin staining limited to tumour cells adjacent to normal thyroid tissue

Metastatic Site: thyroid; cervical lymph nodes

After starting osimertinib for EGFR exon 19-deleted recurrent lung adenocarcinoma, he was disease free 5 months after thyroid surgery.

PubMed CentralRead more →

Afatinib-related kidney injury during treatment for EGFR-positive metastatic lung cancer

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: EGFR-positive.

Metastatic Site: pleura

He continued maintenance bevacizumab and atezolizumab after four combination courses for metastatic disease while his renal function remained impaired but stable.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Tiffany's Patient Story

Patient Info: Tiffany, Female | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Bone: pelvis, right femur, cervical spine

As of March 2023, Tiffany had benefited from Tagrisso plus Cyramza, but later CT findings suggested worsening disease and she had started a new early-stage clinical trial with results pending.

The Patient StoryRead more →

Stage IV EGFR Lung Adenocarcinoma: Emily's Patient Story

Patient Info: Emily Bannister, Female, 40s | Stage IV

Biomarkers: EGFR Exon 19-positive; no other driver mutations present

Metastatic Site: Intrathoracic lymphatic spread

Emily had Stage IV EGFR Exon 19-positive lung adenocarcinoma with a strong early response to trial-based targeted therapy, and later passed away on March 14, 2023 from complications caused by Stage IV lung cancer.

Lung Cancer Research FoundationRead more →

Living with Cancer & My Survivorship : Lung Cancer

Patient Info: Ashley, Female, Under 40 | Stage IV

Biomarkers: EGFR-positive; T790M mutation

As of September 2021, Ashley was living with incurable but treatable EGFR-positive T790M non-small cell lung cancer and described 43 months on treatment/journey while using community support to sustain hope.

The Patient StoryRead more →

Stage IV EGFR Lung Cancer: Ashley's Patient Story

Patient Info: Ashley, Female | Stage IV

Biomarkers: EGFR-positive; T790M-positive

Metastatic Site: Not reported

As of September 2021, Ashley was living with incurable but treatable EGFR-positive/T790M-positive lung cancer on daily osimertinib/Tagrisso with ongoing oncology monitoring and side-effect management.

The Patient StoryRead more →

Cancer Survivor Story: How I Got Diagnosed with Lung Cancer

Patient Info: Ashley, Female, Under 40 | Stage IV

Biomarkers: EGFR-positive; T790M mutation

Metastatic Site: Both lungs

As of August 2021, Ashley had been living for almost 4 years with incurable but treatable EGFR-positive T790M non-small cell lung cancer involving many tiny nodules across both lungs.

The Patient StoryRead more →

Facial paralysis from progression of EGFR-positive metastatic lung cancer improved with osimertinib

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: EGFR exon 21 p.Leu858Arg mutation.

Metastatic Site: brain; leptomeninges and facial nerves

Osimertinib rapidly resolved the bilateral facial weakness and reduced the brain lesions, but after 15 months seizures recurred and three smaller brain metastases had increased in size.

PubMed CentralRead more →

A regressed choroidal metastasis during EGFR-targeted lung cancer treatment

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion.

Metastatic Site: liver; bone; central nervous system; right choroid

The right choroidal metastasis appeared inactive and regressed during systemic treatment, visual acuity remained 20/20, and no local eye treatment was required.

PubMed CentralRead more →